CYP51A1 and vulvovaginal candidiasis: Moreover, in the present study, low binding energy (-9.39 kcal/mol) was obtained for amentoflavone, CYP51, near to that of fluconazole, which is considered by ANVISA as a drug of choice for the treatment of fungal infections (especially vaginal candidiasis caused by Candida species).